Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) saw a large drop in short interest in April. As of April 30th, there was short interest totalling 2,171,585 shares, a drop of 24.8% from the April 15th total of 2,888,176 shares. Based on an average trading volume of 3,600,517 shares, the days-to-cover ratio is currently 0.6 days. Approximately 1.4% of the company’s stock are short sold.

Several brokerages have recently weighed in on ATNM. Oppenheimer set a $5.00 price target on shares of Actinium Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, February 26th. Zacks Investment Research raised shares of Actinium Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.50 price target for the company in a research note on Monday, April 1st. Finally, Maxim Group set a $3.00 price target on shares of Actinium Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, February 5th. Five research analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and a consensus target price of $3.50.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. acquired a new stake in shares of Actinium Pharmaceuticals in the 1st quarter valued at approximately $39,000. Renaissance Technologies LLC lifted its holdings in Actinium Pharmaceuticals by 69.9% during the 1st quarter. Renaissance Technologies LLC now owns 139,347 shares of the biotechnology company’s stock valued at $67,000 after purchasing an additional 57,335 shares during the last quarter. Oppenheimer & Co. Inc. lifted its holdings in Actinium Pharmaceuticals by 69.3% during the 1st quarter. Oppenheimer & Co. Inc. now owns 175,512 shares of the biotechnology company’s stock valued at $84,000 after purchasing an additional 71,840 shares during the last quarter. PNC Financial Services Group Inc. lifted its holdings in Actinium Pharmaceuticals by 23.8% during the 4th quarter. PNC Financial Services Group Inc. now owns 1,031,210 shares of the biotechnology company’s stock valued at $399,000 after purchasing an additional 198,480 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in Actinium Pharmaceuticals by 6.4% during the 3rd quarter. Vanguard Group Inc. now owns 2,575,754 shares of the biotechnology company’s stock valued at $1,909,000 after purchasing an additional 154,403 shares during the last quarter.

NYSEAMERICAN ATNM opened at $0.29 on Wednesday. Actinium Pharmaceuticals has a 12 month low of $0.26 and a 12 month high of $0.87.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last released its quarterly earnings data on Tuesday, March 19th. The biotechnology company reported ($0.06) EPS for the quarter, meeting the consensus estimate of ($0.06).

ILLEGAL ACTIVITY NOTICE: “Actinium Pharmaceuticals Inc (ATNM) Sees Significant Decline in Short Interest” was reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this story on another site, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this story can be viewed at https://theolympiareport.com/2019/05/22/actinium-pharmaceuticals-inc-atnm-sees-significant-decline-in-short-interest.html.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, Iomab-B that is in a pivotal Phase III clinical trial as an induction and conditioning agent in patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to receiving a bone marrow transplant, also known as a hematopoietic stem cell transplant.

Read More: Understanding Options Trading

Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.